Last reviewed · How we verify
BI 11634 IR tablet
At a glance
| Generic name | BI 11634 IR tablet |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers (PHASE1)
- Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BI 11634 IR tablet CI brief — competitive landscape report
- BI 11634 IR tablet updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI